Mga Batayang Estadistika
| CIK | 1857044 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Indaptus Therapeutics, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| September 4, 2025 |
Exhibit 99.1 Indaptus Therapeutics Provides Clinical Update Decoy20 monotherapy induces Partial Response in patient with urothelial cancer and liver metastases Decoy20 combination with PD-1 inhibitor, tislelizumab, demonstrates safety profiles consistent with each agent NEW YORK (September 4, 2025) - Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotech |
|
| September 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 4, 2025 INDAPTUS THERAPEUTICS, INC. |
|
| September 3, 2025 |
430 Park Avenue | New York, New York 10022 | 212.356.0500 | www.hcwco.com Member: FINRA/SIPC Exhibit 10.31 Execution Version March 16, 2025 STRICTLY CONFIDENTIAL Indaptus Therapeutics, Inc. 3 Columbus Circle, 15th Floor New York, NY 10019 Attn: Jeffrey A. Meckler, Chief Executive Officer Dear Mr. Meckler: This letter agreement (this “Agreement”) constitutes the agreement between Indaptus Therapeutics, Inc. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”), that Wainwright shal |
|
| September 3, 2025 |
As filed with the Securities and Exchange Commission on September 3, 2025. As filed with the Securities and Exchange Commission on September 3, 2025. Registration No. 333-289984 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INDAPTUS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 2834 86-3158720 (State or other jurisdiction of i |
|
| September 2, 2025 |
SERIES [A] [B] COMMON STOCK PURCHASE WARRANT INDAPTUS THERAPEUTICS, INC. Exhibit 4.1 SERIES [A] [B] COMMON STOCK PURCHASE WARRANT INDAPTUS THERAPEUTICS, INC. Warrant Shares: Issue Date: , 2025 THIS SERIES [A] [B] COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the [Stockh |
|
| September 2, 2025 |
INDAPTUS THERAPEUTICS, INC. Up to $2,340,000 Shares of Common Stock As Filed Pursuant to Rule 424(b)(5) Registration No. 333-289573 PROSPECTUS SUPPLEMENT (To Prospectus dated August 20, 2025) INDAPTUS THERAPEUTICS, INC. Up to $2,340,000 Shares of Common Stock We have entered into an at-the-market offering agreement, or the Offering Agreement, dated June 1, 2022, as amended, with H.C. Wainwright & Co., LLC, or the Sales Agent or Wainwright, as sales agent relating |
|
| September 2, 2025 |
PRE-FUNDED COMMON STOCK PURCHASE WARRANT INDAPTUS THERAPEUTICS, INC. Exhibit 4.2 PRE-FUNDED COMMON STOCK PURCHASE WARRANT INDAPTUS THERAPEUTICS, INC. Warrant Shares: Issue Date: , 2025 Initial Exercise Date: , 2025 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time o |
|
| September 2, 2025 |
Exhibit 10.30 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of , 2025, between Indaptus Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions se |
|
| September 2, 2025 |
PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT INDAPTUS THERAPEUTICS, INC. Exhibit 4.3 PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT INDAPTUS THERAPEUTICS, INC. Warrant Shares: Issue Date: , 2025 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the [Stoc |
|
| September 2, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-1 (Form Type) Indaptus Therapeutics, Inc. |
|
| September 2, 2025 |
As filed with the Securities and Exchange Commission on September 2, 2025. As filed with the Securities and Exchange Commission on September 2, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INDAPTUS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 2834 86-3158720 (State or other jurisdiction of incorporation or organizat |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 13, 2025 INDAPTUS THERAPEUTICS, INC. |
|
| August 13, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Indaptus Therapeutics, Inc. |
|
| August 13, 2025 |
As filed with the Securities and Exchange Commission on August 13, 2025 As filed with the Securities and Exchange Commission on August 13, 2025 Registration No. |
|
| August 13, 2025 |
Exhibit 99.1 Indaptus Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update — Company Initiates Combination Trial and Strengthens Balance Sheet to Support Continued Clinical Progress — NEW YORK (August 13, 2025) - Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative can |
|
| August 13, 2025 |
Exhibit 10.3 THIS PRE-FUNDED WARRANT AND THE SHARES OF COMMON STOCK ISSUED UPON ITS EXERCISE ARE SUBJECT TO THE RESTRICTIONS ON TRANSFER SET FORTH IN SECTION 5 OF THIS PRE-FUNDED WARRANT Warrant No. CS-[●] Number of Shares: [●] (subject to adjustment) Date of Issuance: [●], 2025 Original Issue Date (as defined in subsection 2(a)): [●], 2025 Indaptus Therapeutics, Inc. Pre-Funded Common Stock Purch |
|
| August 13, 2025 |
As filed with the Securities and Exchange Commission on August 13, 2025 As filed with the Securities and Exchange Commission on August 13, 2025 Registration No. |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40652 Indaptus Th |
|
| August 13, 2025 |
Exhibit 107 Calculation of Filing Fee Table Registration Statement on Form S-3 (Form Type) INDAPTUS THERAPEUTICS, INC. |
|
| July 29, 2025 |
Unregistered Sales of Equity Securities, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 25, 2025 INDAPTUS THERAPEUTICS, INC. |
|
| July 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 14, 2025 INDAPTUS THERAPEUTICS, INC. |
|
| July 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 30, 2025 INDAPTUS THERAPEUTICS, INC. |
|
| July 1, 2025 |
Exhibit 99.1 Indaptus Therapeutics, Inc. Announces Additional Sale of $3.4 Million in Private Placement of Convertible Notes and Warrants NEW YORK, July 1, 2025 (GLOBE NEWSWIRE) — Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced the additional sale of approximate |
|
| June 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 25, 2025 INDAPTUS THERAPEUTICS, INC. |
|
| June 26, 2025 |
Indaptus Therapeutics Announces Reverse Stock Split Exhibit 99.1 Indaptus Therapeutics Announces Reverse Stock Split NEW YORK (June 25, 2025) - Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced that its Board of Directors has approved a one-for-twenty eight reverse stock split of its common stock t |
|
| June 26, 2025 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF INDAPTUS THERAPEUTICS, INC. Indaptus Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”) hereby certifies as follows: A. The name of the Corporation is Indaptus Therapeutics, Inc. The Corporation was originally incorporated under the name of |
|
| June 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| June 13, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of [●], 2025, between Indaptus Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, the Company seeks to sell an aggrega |
|
| June 13, 2025 |
Exhibit 10.3 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUED UPON ITS EXERCISE ARE SUBJECT TO THE RESTRICTIONS ON TRANSFER SET FORTH IN SECTION 5 OF THIS WARRANT Warrant No. CS-[●] Number of Shares: [●] (subject to adjustment) Date of Issuance: [●], 2025 Original Issue Date (as defined in subsection 2(a)): [●], 2025 Indaptus Therapeutics, Inc. Common Stock Purchase Warrant (Void after 5:00 p.m. |
|
| June 13, 2025 |
Form of Convertible Promissory Note Exhibit 10.2 CONVERTIBLE PROMISSORY NOTE THIS NOTE AND THE SECURITIES ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION, AND MAY NOT BE SOLD, ASSIGNED, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF EXCEPT IN COMPLIANCE WITH, OR PURSUANT TO AN EXEMPTION FROM, THE |
|
| June 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 12, 2025 INDAPTUS THERAPEUTICS, INC. |
|
| June 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| June 13, 2025 |
Exhibit 99.1 Indaptus Therapeutics, Inc. Announces Sale of $2.3 Million in Private Placement of Convertible Notes and Warrants NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) — Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced the sale of approximately $2.3 million in ag |
|
| June 13, 2025 |
Exhibit 10.4 May 9, 2025 STRICTLY CONFIDENTIAL Jeffrey Meckler Indaptus Therapeutics, Inc. 3 Columbus Circle, 15th Floor New York, NY 10019 PLACEMENT AGENT AGREEMENT This Placement Agent Agreement (“Agreement”) is made by and between Indaptus Therapeutics, Inc., (the “Company”), and Paulson Investment Company, LLC, a Delaware limited liability company (the “Placement Agent”), as of the date first |
|
| June 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 10, 2025 INDAPTUS THERAPEUTICS, INC. |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40652 Indaptus T |
|
| May 14, 2025 |
Indaptus Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update Exhibit 99.1 Indaptus Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update NEW YORK (May 14, 2025) - Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced financial results for the first quarter ended March 31, 2025, |
|
| May 14, 2025 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 14, 2025 INDAPTUS THERAPEUTICS, INC. |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 13, 2025 |
Exhibit 19.1 INDAPTUS THERAPEUTICS, INC. INSIDER TRADING POLICY This Insider Trading Policy (the “Policy”) sets forth the policy for directors, officers, employees, consultants and contractors of Indaptus Therapeutics, Inc. and its subsidiaries (the “Company”) with respect to transactions in the Company’s securities or securities of certain other publicly traded companies while in possession of co |
|
| March 13, 2025 |
Exhibit 99.1 Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update ● Company Achieves Key Clinical Milestone with more than 20 Patients Enrolled in Weekly Dosing Cohort of Phase 1 Trial of Decoy20 ● Pharmacodynamic immune activation biomarker and pharmacokinetics profiles in initial data sets appear to meet or exceed initial expectations ● E |
|
| March 13, 2025 |
As filed with the Securities and Exchange Commission on March 13, 2025 As filed with the Securities and Exchange Commission on March 13, 2025 Registration No. |
|
| March 13, 2025 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 13, 2025 INDAPTUS THERAPEUTICS, INC. |
|
| March 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-40652 INDAPTUS THERAP |
|
| February 13, 2025 |
Indaptus Therapeutics, Inc. 3 Columbus Circle 15th Floor New York, NY 10019 Indaptus Therapeutics, Inc. 3 Columbus Circle 15th Floor New York, NY 10019 February 13, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: Indaptus Therapeutics, Inc. (CIK 0001857044) Registration Statement No. 333-284863 on Form S-1 (the “Registration Statement”) Ladies and Gentlemen: Indaptus Therapeutics, Inc. (the “Reg |
|
| February 12, 2025 |
As filed with the Securities and Exchange Commission on February 12, 2025 As filed with the Securities and Exchange Commission on February 12, 2025 Registration No. |
|
| February 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 12, 2025 INDAPTUS THERAPEUTICS, INC. |
|
| February 12, 2025 |
Exhibit 107 Registration Statement on Form S-1 (Form Type) INDAPTUS THERAPEUTICS, INC. |
|
| February 12, 2025 |
Exhibit 10.1 STANDBY EQUITY PURCHASE AGREEMENT THIS STANDBY EQUITY PURCHASE AGREEMENT (this “Agreement”) dated as of February 12, 2025, is made by and between YA II PN, LTD., a Cayman Islands exempt limited company (the “Investor”), and INDAPTUS THERAPEUTICS, INC., a company incorporated under the laws of the State of Delaware (the “Company”). The Investor and the Company may be referred to herein |
|
| February 11, 2025 |
Indaptus Therapeutics, Inc. 3 Columbus Circle 15th Floor New York, NY 10019 Indaptus Therapeutics, Inc. 3 Columbus Circle 15th Floor New York, NY 10019 February 11, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: Indaptus Therapeutics, Inc. (CIK 0001857044) Registration Statement No. 333-284707 on Form S-3 (the “Registration Statement”) Ladies and Gentlemen: Indaptus Therapeutics, Inc. (the “Reg |
|
| February 5, 2025 |
Exhibit 107 Calculation of Filing Fee Table Registration Statement on Form S-3 (Form Type) INDAPTUS THERAPEUTICS, INC. |
|
| February 5, 2025 |
As filed with the Securities and Exchange Commission on February 5, 2025 As filed with the Securities and Exchange Commission on February 5, 2025 Registration No. |
|
| January 31, 2025 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 31, 2025 INDAPTUS THERAPEUTICS, INC. |
|
| January 14, 2025 |
Exhibit 10.4 December 12, 2024 STRICTLY CONFIDENTIAL Jeffrey Meckler Indaptus Therapeutics, Inc. 3 Columbus Circle, 15th Floor New York, NY 10019 PLACEMENT AGENT AGREEMENT This Placement Agent Agreement (“Agreement”) is made by and between Indaptus Therapeutics, Inc., (the “Company”), and Paulson Investment Company, LLC, a Delaware limited liability company (the “Placement Agent”), as of the date |
|
| January 14, 2025 |
Exhibit 10.2 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUED UPON ITS EXERCISE ARE SUBJECT TO THE RESTRICTIONS ON TRANSFER SET FORTH IN SECTION 5 OF THIS WARRANT Warrant No. CS-[●] Number of Shares: [●] (subject to adjustment) Date of Issuance: [●], 2024 Original Issue Date (as defined in subsection 2(a)): [●], 2024 Indaptus Therapeutics, Inc. Common Stock Purchase Warrant (Void after 5:00 p.m. |
|
| January 14, 2025 |
Form of Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 12, 2025, between Indaptus Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and cond |
|
| January 14, 2025 |
Exhibit 99.1 Indaptus Therapeutics, Inc. Announces $2.25 Million Private Placement Priced At-The-Market Under Nasdaq Rules NEW YORK, January 13, 2025 (GLOBE NEWSWIRE) — Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced that it has entered into securities purchase |
|
| January 14, 2025 |
Form of Placement Agent Warrant Exhibit 10.3 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUED UPON ITS EXERCISE ARE SUBJECT TO THE RESTRICTIONS ON TRANSFER SET FORTH IN SECTION 5 OF THIS WARRANT Warrant No. CS-[●] Number of Shares: [●] (subject to adjustment) Date of Issuance: [●], 2025 Original Issue Date (as defined in subsection 2(a)): [●], 2025 Indaptus Therapeutics, Inc. Placement Agent Common Stock Purchase Warrant (Void |
|
| January 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 12, 2025 INDAPTUS THERAPEUTICS, INC. |
|
| December 30, 2024 |
Indaptus Therapeutics, Inc. 3 Columbus Circle 15th Floor New York, NY 10019 Indaptus Therapeutics, Inc. 3 Columbus Circle 15th Floor New York, NY 10019 December 30, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: Indaptus Therapeutics, Inc. (CIK 0001857044) Registration Statement No. 333-284026 on Form S-1 (the “Registration Statement”) Ladies and Gentlemen: Indaptus Therapeutics, Inc. (the “Reg |
|
| December 23, 2024 |
As filed with the Securities and Exchange Commission on December 23, 2024 As filed with the Securities and Exchange Commission on December 23, 2024 Registration No. |
|
| December 23, 2024 |
Exhibit 107 Calculation of Filing Fee Table Registration Statement on Form S-1 (Form Type) INDAPTUS THERAPEUTICS, INC. |
|
| November 26, 2024 |
INDP / Indaptus Therapeutics, Inc. / Meckler Jeffrey A Activist Investment SC 13D/A 1 formsc13da.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Indaptus Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 45339J105 (CUSIP Number) Jeffrey A. Meckler c/o Indaptus Therapeutics, Inc. 3 Columbus Circle, 15th Floor New Yo |
|
| November 22, 2024 |
Exhibit 1.1 October 29, 2024 STRICTLY CONFIDENTIAL Jeffrey Meckler Indaptus Therapeutics, Inc. 3 Columbus Circle, 15th Floor New York, NY 10019 PLACEMENT AGENT AGREEMENT This Placement Agent Agreement (“Agreement”) is made by and between Indaptus Therapeutics, Inc., (the “Company”), and Paulson Investment Company, LLC, a Delaware limited liability company (the “Placement Agent”), as of the date fi |
|
| November 22, 2024 |
Exhibit 10.3 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUED UPON ITS EXERCISE ARE SUBJECT TO THE RESTRICTIONS ON TRANSFER SET FORTH IN SECTION 5 OF THIS WARRANT Warrant No. CS-[●] Number of Shares: [●] (subject to adjustment) Date of Issuance: [●], 2024 Original Issue Date (as defined in subsection 2(a)): [●], 2024 Indaptus Therapeutics, Inc. Placement Agent Common Stock Purchase Warrant (Void |
|
| November 22, 2024 |
Exhibit 99.1 Indaptus Therapeutics, Inc. Announces $2.135 Million Registered Direct Offering and Concurrent Private Placement NEW YORK, November 22, 2024 – (GLOBE NEWSWIRE) – Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced that it has entered into securities pur |
|
| November 22, 2024 |
Exhibit 10.2 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUED UPON ITS EXERCISE ARE SUBJECT TO THE RESTRICTIONS ON TRANSFER SET FORTH IN SECTION 5 OF THIS WARRANT Warrant No. CS-[●] Number of Shares: [●] (subject to adjustment) Date of Issuance: [●], 2024 Original Issue Date (as defined in subsection 2(a)): [●], 2024 Indaptus Therapeutics, Inc. Common Stock Purchase Warrant (Void after 5:00 p.m. |
|
| November 22, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of November 22, 2024, between Indaptus Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and con |
|
| November 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 22, 2024 INDAPTUS THERAPEUTICS, INC. |
|
| November 22, 2024 |
Indaptus Therapeutics, Inc. 1,817,017 Shares of Common Stock As filed Pursuant to Rule 424(b)(5) Registration No. 333-267236 PROSPECTUS SUPPLEMENT (To Prospectus dated September 9, 2022) Indaptus Therapeutics, Inc. 1,817,017 Shares of Common Stock We are offering 1,817,017 shares of our common stock, par value $0.01 per share (“common stock”) in a registered direct offering pursuant to this prospectus supplement and the accompanying prospectus and securitie |
|
| November 12, 2024 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 12, 2024 INDAPTUS THERAPEUTICS, INC. |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40652 Indapt |
|
| November 12, 2024 |
Indaptus Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update Exhibit 99.1 Indaptus Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update NEW YORK (November 12, 2024) - Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced financial results for the third quarter ended September |
|
| October 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 17, 2024 INDAPTUS THERAPEUTICS, INC. |
|
| October 10, 2024 |
INDP / Indaptus Therapeutics, Inc. / Meckler Jeffrey A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Indaptus Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 45339J105 (CUSIP Number) Jeffrey A. Meckler c/o Indaptus Therapeutics, Inc. 3 Columbus Circle, 15th Floor New York, NY 10019 (646) 427-2727 |
|
| September 18, 2024 |
September 18, 2024 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| September 12, 2024 |
As filed with the Securities and Exchange Commission on September 12, 2024 As filed with the Securities and Exchange Commission on September 12, 2024 Registration No. |
|
| September 12, 2024 |
Exhibit 107 Calculation of Filing Fee Table Registration Statement on Form S-1 (Form Type) INDAPTUS THERAPEUTICS, INC. |
|
| August 12, 2024 |
Exhibit 107.1 CALCULATION OF FILING FEE TABLE FORM S-8 (Form Type) INDAPTUS THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Table I: Newly Registered Securities Plan Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Amended and Restated |
|
| August 12, 2024 |
Indaptus Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update Exhibit 99.1 Indaptus Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update NEW YORK (August 12, 2024) - Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced financial results for the second quarter ended June 30, 2 |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40652 Indaptus Th |
|
| August 12, 2024 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 12, 2024 INDAPTUS THERAPEUTICS, INC. |
|
| August 12, 2024 |
As filed with the Securities and Exchange Commission on August 12, 2024 As filed with the Securities and Exchange Commission on August 12, 2024 Registration No. |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 7, 2024 INDAPTUS THERAPEUTICS, INC. |
|
| August 8, 2024 |
Exhibit 1.1 July 23, 2024 STRICTLY CONFIDENTIAL Jeffrey Meckler, CEO Indaptus Therapeutics, Inc Three Columbus Circle, 15th Floor New York, NY 10019 PLACEMENT AGENT AGREEMENT This Placement Agent Agreement (“Agreement”) is made by and between Indaptus Therapeutics, Inc, (the “Company”), and Paulson Investment Company, LLC, a Delaware limited liability company (the “Placement Agent”), as of the dat |
|
| August 8, 2024 |
Exhibit 99.1 Indaptus Therapeutics, Inc. Announces $3.0 Million Registered Direct Offering and Concurrent Private Placement NEW YORK, Aug. 07, 2024 – (GLOBE NEWSWIRE) – Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced that it has entered into securities purchase |
|
| August 8, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of August 7, 2024, between Indaptus Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condit |
|
| August 8, 2024 |
Exhibit 10.2 FORM OF COMMON STOCK WARRANT THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUED UPON ITS EXERCISE ARE SUBJECT TO THE RESTRICTIONS ON TRANSFER SET FORTH IN SECTION 5 OF THIS WARRANT Warrant No. CS-[●] Number of Shares: [●] (subject to adjustment) Date of Issuance: August 8, 2024 Original Issue Date (as defined in subsection 2(a)): August 8, 2024 Indaptus Therapeutics, Inc. Common Stock |
|
| August 7, 2024 |
Indaptus Therapeutics, Inc. 1,643,837 Shares of Common Stock As filed Pursuant to Rule 424(b)(5) Registration No. 333-267236 PROSPECTUS SUPPLEMENT (To Prospectus dated September 9, 2022) Indaptus Therapeutics, Inc. 1,643,837 Shares of Common Stock We are offering 1,643,837 shares of our common stock, par value $0.01 per share (“common stock”) in a registered direct offering pursuant to this prospectus supplement and the accompanying prospectus and a securit |
|
| August 6, 2024 |
INDAPTUS THERAPEUTICS, INC. Common Stock As Filed Pursuant to Rule 424(b)(5) Registration No. 333-267236 PROSPECTUS SUPPLEMENT (To Prospectus dated September 9, 2022 and Prospectus Supplements dated September 9, 2022 and March 27, 2023) INDAPTUS THERAPEUTICS, INC. Common Stock This prospectus supplement (the “Prospectus Supplement”) supplements the prospectus dated September 9, 2022 and the prospectus supplements dated September 9, 2022, |
|
| June 7, 2024 |
Exhibit 10.1 INDAPTUS THERAPEUTICS, INC. (Formerly INTEC PARENT, INC.) 2021 STOCK INCENTIVE PLAN (as amended and restated effective as of June 6, 2024) Unless otherwise defined, terms used herein shall have the meaning ascribed to them in Section 2 hereof. 1. PURPOSE; TYPES OF AWARDS; CONSTRUCTION. 1.1. Purpose. The purpose of this 2021 Stock Incentive Plan (as amended, this “Plan”) is to afford a |
|
| June 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 6, 2024 INDAPTUS THERAPEUTICS, INC. |
|
| May 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 22, 2024 INDAPTUS THERAPEUTICS, INC. |
|
| May 8, 2024 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 8, 2024 INDAPTUS THERAPEUTICS, INC. |
|
| May 8, 2024 |
Exhibit 99.1 Indaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update Company to present poster at American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2024 highlighting initial results from its Phase 1 clinical trial of Decoy20 NEW YORK (May 8, 2024) - Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical sta |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40652 Indaptus T |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 25, 2024 INDAPTUS THERAPEUTICS, INC. |
|
| March 13, 2024 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 13, 2024 INDAPTUS THERAPEUTICS, INC. |
|
| March 13, 2024 |
Indaptus Therapeutics, Inc. Policy for Recovery of Erroneously Awarded Compensation Exhibit 97.1 INDAPTUS THERAPEUTICS, INC. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION Indaptus Therapeutics, Inc. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of October 2, 2023 (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined herein are defined in Section 11. 1. Persons Subje |
|
| March 13, 2024 |
Exhibit 10.8 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”), effective as of August 7, 2023 (the “Effective Date”), is between Indaptus Therapeutics, Inc. (the “Company”) and Roger J. Waltzman (the “Executive”). WITNESSETH WHEREAS, the Company desires to employ the Executive as its Chief Medical Officer as of the Effective Date, and the Executive desires to accept such employmen |
|
| March 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-40652 INDAPTUS THERAP |
|
| March 13, 2024 |
INDAPTUS THERAPEUTICS, INC. Up to $5,244,831.06 of Common Stock As Filed Pursuant to Rule 424(b)(5) Registration No. 333-267236 PROSPECTUS SUPPLEMENT (To Prospectus dated September 9, 2022 and Prospectus Supplements dated September 9, 2022 and March 27, 2023) INDAPTUS THERAPEUTICS, INC. Up to $5,244,831.06 of Common Stock This prospectus supplement (the “Prospectus Supplement”) supplements the prospectus dated September 9, 2022 and the prospectus supplements d |
|
| March 13, 2024 |
Exhibit 99.1 Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update ● Announced Positive Results from Second Cohort of Phase 1 Trial of Decoy20 ● Initiating Multi-Dosing for patients with solid tumors NEW YORK (March 13, 2024) - Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) today announced financial results for the |
|
| March 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 4, 2024 INDAPTUS THERAPEUTICS, INC. |
|
| January 23, 2024 |
Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF INDAPTUS THERAPEUTICS, INC. ARTICLE 1 CORPORATE OFFICES 1.1 REGISTERED OFFICE. The registered office of the Corporation shall be fixed in the Corporation’s Certificate of Incorporation, as the same may be amended or restated from time to time (the “Certificate of Incorporation”). 1.2 OTHER OFFICES. The Corporation’s board of directors (the “Board”) may at |
|
| January 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 22, 2024 INDAPTUS THERAPEUTICS, INC. |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 6, 2023 INDAPTUS THERAPEUTICS, INC. |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40652 Indapt |
|
| November 6, 2023 |
Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update Exhibit 99.1 Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update NEW YORK (November 6, 2023) - Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) today announced financial results for the third quarter ended September 30, 2023 and provided a corporate update. “We continue to be encouraged by early results from our first cohort of p |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2023 INDAPTUS THERAPEUTICS, INC. |
|
| October 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2023 INDAPTUS THERAPEUTICS, INC. |
|
| August 17, 2023 |
INDP / Indaptus Therapeutics Inc / Anderson Glen R. Passive Investment SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Indaptus Therapeutics, Inc. (Name of Issuer) Common Stock, Par Value $0.01 Per Share (Title of Class of Securities) 45339J 105 (CUSIP Number) Glen R. Anderson Anderson Family Trust 101 South 200 East Suite 700 Salt Lake City, Ut |
|
| August 14, 2023 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 14, 2023 INDAPTUS THERAPEUTICS, INC. |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40652 Indaptus Th |
|
| August 14, 2023 |
Indaptus Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update Exhibit 99.1 Indaptus Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update NEW YORK (August 14, 2023) - Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update. “We have recently announced the completion of the first cohort of patients in |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 10, 2023 INDAPTUS THERAPEUTICS, INC. |
|
| May 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 25, 2023 INDAPTUS THERAPEUTICS, INC. |
|
| May 11, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 11, 2023 INDAPTUS THERAPEUTICS, INC. |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40652 Indaptus T |
|
| May 11, 2023 |
Exhibit 10.1 Indaptus Therapeutics, Inc. Non-Employee Director Compensation Program Non-employee members of the board of directors (the “Board”) of Indaptus Therapeutics, Inc. (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”), which shall amend and restate in its entirety the Company’s existing Directors’ Com |
|
| May 11, 2023 |
Exhibit 99.1 Indaptus Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update Enrollment Continues for Phase 1 Clinical Trial of Decoy20 for Treatment of Solid Tumors with First Patient Dosed In March 2023 NEW YORK (May 11, 2023) - Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), today announced financial results for the first quarter ended |
|
| April 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 27, 2023 |
INDAPTUS THERAPEUTICS, INC. Up to $3,717,317.70 of Common Stock As Filed Pursuant to Rule 424(b)(5) Registration No. 333-267236 PROSPECTUS SUPPLEMENT (To Prospectus and Prospectus Supplement dated September 9, 2022) INDAPTUS THERAPEUTICS, INC. Up to $3,717,317.70 of Common Stock This Prospectus Supplement supplements the prospectus and the prospectus supplement, each dated September 9, 2022 (together, the “ATM Prospectus”), relating to the offer and sale of sh |
|
| March 24, 2023 |
As filed with the Securities and Exchange Commission on March 24, 2023 As filed with the Securities and Exchange Commission on March 24, 2023 Registration No. |
|
| March 24, 2023 |
Exhibit 107.1 CALCULATION OF FILING FEE TABLE FORM S-8 (Form Type) INDAPTUS THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Table I: Newly Registered Securities Plan Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 2021 Stock Incentive |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 22, 2023 INDAPTUS THERAPEUTICS, INC. |
|
| March 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-40652 INDAPTUS THERAP |
|
| March 17, 2023 |
Exhibit 99.1 Indaptus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update Enrollment Underway in Phase 1 Clinical Trial of Decoy20 for Treatment of Solid Tumors with First Patient Dosed In March 2023 NEW YORK (March 17, 2023) - Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), today announced financial results for the fourth |
|
| March 17, 2023 |
Exhibit 10.2 NOTICE OF OPTION GRANT You have been granted the following options (the “Options” or “Award”) to purchase shares of Common Stock, par value US$0.01 each (the “Shares”), of Indaptus Therapeutics, Inc. (the “Company”), pursuant and subject to the terms and conditions of the Company’s 2021 Stock Incentive Plan (as may be amended from time to time, the “Plan”), and the additional terms an |
|
| March 17, 2023 |
Indaptus Therapeutics, Inc. 2021 Stock Incentive Plan Exhibit 10.1 INDAPTUS THERAPEUTICS, INC. (Formerly INTEC PARENT, INC.) 2021 STOCK INCENTIVE PLAN (dated as of June 21, 2021) Unless otherwise defined, terms used herein shall have the meaning ascribed to them in Section 2 hereof. 1. PURPOSE; TYPES OF AWARDS; CONSTRUCTION. 1.1. Purpose. The purpose of this 2021 Stock Incentive Plan (as amended, this “Plan”) is to afford an incentive to Service Prov |
|
| March 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 17, 2023 INDAPTUS THERAPEUTICS, INC. |
|
| February 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 13, 2023 INDAPTUS THERAPEUTICS, INC. |
|
| December 30, 2022 |
Indaptus Therapeutics, Inc. 4,000,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-269000 Indaptus Therapeutics, Inc. 4,000,000 Shares of Common Stock This prospectus relates to the offer and sale of up to 4,000,000 shares of our common stock, par value $0.01 per share, by Lincoln Park Capital Fund, LLC, which we refer to in this prospectus as Lincoln Park or the selling stockholder. The shares of common stock to which this p |
|
| December 30, 2022 |
Indaptus Therapeutics, Inc. 3 Columbus Circle 15th Floor New York, New York 10019 CORRESP 1 filename1.htm Indaptus Therapeutics, Inc. 3 Columbus Circle 15th Floor New York, New York 10019 December 30, 2022 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Indaptus Therapeutics, Inc. Registration Statement on Form S-1 File No. 333-269000 VIA EDGAR Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of |
|
| December 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 22, 2022 INDAPTUS THERAPEUTICS, INC. |
|
| December 23, 2022 |
Exhibit 10.1 EXECUTION VERSION PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (the ?Agreement?), dated as of December 22, 2022, is made by and between INDAPTUS THERAPEUTICS, INC., a Delaware corporation (the ?Company?), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the ?Investor?). WHEREAS: Subject to the terms and conditions set forth in this Agreement, the Company wishes |
|
| December 23, 2022 |
Exhibit 10.2 EXECUTION VERSION REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this ?Agreement?), dated as of December 22, 2022, is entered into by and between INDAPTUS THERAPEUTICS, INC., a Delaware corporation (the ?Company?), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with its permitted assigns, the ?Investor?). Capitalized terms used h |
|
| December 23, 2022 |
As filed with the Securities and Exchange Commission on December 23, 2022 As filed with the Securities and Exchange Commission on December 23, 2022 Registration No. |
|
| December 23, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Indaptus Therapeutics, Inc. |
|
| November 10, 2022 |
Exhibit 99.1 Indaptus Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update Company Remains On Track to Initiate Phase 1 Clinical Trial of Decoy20 for Treatment of Solid Tumors in Q4 2022 NEW YORK (November 10, 2022) - Indaptus Therapeutics, Inc. (Nasdaq: INDP) (?Indaptus? or the ?Company?), today announces financial results for the third quarter ended September 3 |
|
| November 10, 2022 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 10, 2022 INDAPTUS THERAPEUTICS, INC. |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40652 Indapt |
|
| September 30, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 29, 2022 INDAPTUS THERAPEUTICS, INC. |
|
| September 9, 2022 |
Indaptus Therapeutics, Inc. 3 Columbus Circle, 15th Floor New York, NY 10019 Indaptus Therapeutics, Inc. 3 Columbus Circle, 15th Floor New York, NY 10019 September 9, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Indaptus Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-265350 Ladies and Gentlemen: On June 1, 2022, Indaptus Therapeutics, Inc. (the ?Company?) filed the Regist |
|
| September 7, 2022 |
Indaptus Therapeutics, Inc. 3 Columbus Circle 15th Floor New York, New York 10019 Indaptus Therapeutics, Inc. 3 Columbus Circle 15th Floor New York, New York 10019 September 7, 2022 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Indaptus Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-267236 VIA EDGAR Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Indap |
|
| September 1, 2022 |
As filed with the Securities and Exchange Commission on September 1, 2022 As filed with the Securities and Exchange Commission on September 1, 2022 Registration No. |
|
| September 1, 2022 |
Exhibit 1.2 AT THE MARKET OFFERING AGREEMENT June 1, 2022 H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: Indaptus Therapeutics, Inc., a corporation organized under the laws of Delaware (the ?Company?), confirms its agreement (this ?Agreement?) with H.C. Wainwright & Co., LLC (the ?Manager?) as follows: 1. Definitions. The terms that follow, when used in t |
|
| September 1, 2022 |
Form of Subordinated Indenture Exhibit 4.2 INDAPTUS THERAPEUTICS, INC. TO [], as Trustee GUARANTEED TO THE EXTENT SET FORTH HEREIN BY THE GUARANTORS NAMED HEREIN INDENTURE Dated as of [], 20[] SUBORDINATED DEBT SECURITIES TABLE OF CONTENTS Page Article One Definitions and Other Provisions of General Application 1 Section 101 Definitions 1 Section 102 Compliance Certificates and Opinions 11 Section 103 Form of Documents Delivere |
|
| September 1, 2022 |
Exhibit 4.1 INDAPTUS THERAPEUTICS, INC. TO [], as Trustee GUARANTEED TO THE EXTENT SET FORTH HEREIN BY THE GUARANTORS NAMED HEREIN INDENTURE Dated as of [], 20[] SENIOR DEBT SECURITIES TABLE OF CONTENTS Page Article One Definitions and Other Provisions of General Application 1 Section 101 Definitions 1 Section 102 Compliance Certificates and Opinions 10 Section 103 Form of Documents Delivered to T |
|
| September 1, 2022 |
Exhibit 1.3 September 1, 2022 H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: Reference is hereby made to that certain At The Market Offering Agreement dated June 1, 2022 (the “ATM Agreement”) by and between Indaptus Therapeutics, Inc., a corporation organized under the laws of Delaware (the “Company”) and H.C. Wainwright & Co., LLC (the “Manager”). Capita |
|
| September 1, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Indaptus Therapeutics, Inc. |
|
| August 8, 2022 |
Exhibit 99.1 Indaptus Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update U.S. Food and Drug Administration (FDA) Cleared Investigational New Drug (IND) Application for Decoy20 On Track to Initiate Phase 1 Clinical Trial of Decoy20 for Treatment of Solid Tumors in 2022 NEW YORK (August 8, 2022) - Indaptus Therapeutics, Inc. (Nasdaq: INDP) (?Indaptus? or the ?Co |
|
| August 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40652 Indaptus Th |
|
| August 8, 2022 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 8, 2022 INDAPTUS THERAPEUTICS, INC. |
|
| August 4, 2022 |
DEF 14A 1 formdef14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| July 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 20, 2022 INDAPTUS THERAPEUTICS, INC. |
|
| July 21, 2022 |
Exhibit 3.1 AMENDMENT NO. 1 TO AMENDED AND RESTATED BYLAWS OF INDAPTUS THERAPEUTICS, INC. This Amendment No. 1 (this ?Amendment?) to the Amended and Restated Bylaws of Indaptus Therapeutics, Inc., a Delaware corporation, dated July 23, 2021 (the ?Bylaws?), is made as of July 20, 2022 in accordance with adopted in accordance with Article 9 of the Bylaws. Capitalized terms used herein and not otherw |
|
| July 8, 2022 |
INDP / Indaptus Therapeutics, Inc. / Anderson Glen R. Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Indaptus Therapeutics, Inc. (Name of Issuer) Common Stock, Par Value $0.01 Per Share (Title of Class of Securities) 45339J 105 (CUSIP Number) Glen R. Anderson Anderson Family Trust 101 South 200 East Suite 700 Salt Lake City, Utah 84111 +1.6 |
|
| June 1, 2022 |
Exhibit 4.1 INDAPTUS THERAPEUTICS, INC. TO [], as Trustee GUARANTEED TO THE EXTENT SET FORTH HEREIN BY THE GUARANTORS NAMED HEREIN INDENTURE Dated as of [], 20[] SENIOR DEBT SECURITIES TABLE OF CONTENTS Page Article One Definitions and Other Provisions of General Application 1 Section 101 Definitions 1 Section 102 Compliance Certificates and Opinions 10 Section 103 Form of Documents Delivered to T |
|
| June 1, 2022 |
EX-1.2 2 ex1-2.htm Exhibit 1.2 AT THE MARKET OFFERING AGREEMENT June 1, 2022 H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: Indaptus Therapeutics, Inc., a corporation organized under the laws of Delaware (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows: 1. Definitions. The terms that fol |
|
| June 1, 2022 |
Form of Subordinated Indenture Exhibit 4.2 INDAPTUS THERAPEUTICS, INC. TO [], as Trustee GUARANTEED TO THE EXTENT SET FORTH HEREIN BY THE GUARANTORS NAMED HEREIN INDENTURE Dated as of [], 20[] SUBORDINATED DEBT SECURITIES TABLE OF CONTENTS Page Article One Definitions and Other Provisions of General Application 1 Section 101 Definitions 1 Section 102 Compliance Certificates and Opinions 11 Section 103 Form of Documents Delivere |
|
| June 1, 2022 |
As filed with the Securities and Exchange Commission on June 1, 2022 As filed with the Securities and Exchange Commission on June 1, 2022 Registration No. |
|
| June 1, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Indaptus Therapeutics, Inc. |
|
| June 1, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 1, 2022 INDAPTUS THERAPEUTICS, INC. |
|
| May 27, 2022 |
Indaptus Therapeutics, Inc. 3 Columbus Circle, 15th Floor New York, NY 10019 Indaptus Therapeutics, Inc. 3 Columbus Circle, 15th Floor New York, NY 10019 May 27, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Indaptus Therapeutics, Inc. Registration Statement on Form S-3 Post-Effective Amendment No. 1 dated August 16, 2021 and filed on August 16, 2021 and Post-Effective Amendment No. 1 dated A |
|
| May 19, 2022 |
Exhibit 99.1 Indaptus Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Decoy20 in Solid Tumors NEW YORK (May 19, 2022) - Indaptus Therapeutics, Inc. (Nasdaq: INDP) (?Indaptus? or the ?Company?), today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company?s Investigational New Drug (IND) application for a |
|
| May 19, 2022 |
Regulation FD Disclosure, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 19, 2022 INDAPTUS THERAPEUTICS, INC. |
|
| May 12, 2022 |
Exhibit 99.1 Indaptus Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update Announces Submission of Investigational New Drug (IND) Application for Decoy20 On Track to Initiate Phase 1 Clinical Trial of Decoy20 for Treatment of Solid Tumors in Second Half of 2022 NEW YORK (May 12, 2022) - Indaptus Therapeutics, Inc. (Nasdaq: INDP) (?Indaptus? or the ?Company?), tod |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40652 Indaptus T |
|
| May 12, 2022 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 12, 2022 INDAPTUS THERAPEUTICS, INC. |
|
| March 25, 2022 |
Indaptus Therapeutics, Inc. 3 Columbus Circle, 15th Floor New York, NY 10019 AW 1 formaw.htm Indaptus Therapeutics, Inc. 3 Columbus Circle, 15th Floor New York, NY 10019 March 25, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Indaptus Therapeutics, Inc. Registration Statement on Form S-1 Post-Effective Amendment No. 1 File No. 333-230016 Ladies and Gentlemen: Pursuant to Rule 477 under the Se |
|
| March 22, 2022 |
As filed with the Securities and Exchange Commission on March 22, 2022 As filed with the Securities and Exchange Commission on March 22, 2022 Registration No. |
|
| March 22, 2022 |
Power of Attorney for Mark J. Gilbert, M.D. Exhibit 24.2 POWER OF ATTORNEY March 22, 2022 The undersigned director of Indaptus Therapeutics, Inc. hereby constitutes and appoints Jeffrey A. Meckler and Nir Sassi, and each of them, with full power to act without the other, as such person?s true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, i |
|
| March 22, 2022 |
Exhibit 107 EX-FILING FEES Calculation of Filing Fee Tables Form S-1 (Form Type) Indaptus Therapeutics, Inc. |
|
| March 21, 2022 |
Exhibit 4.1 DESCRIPTION OF SECURITIES General The following description of our capital stock is a summary. This summary is subject to the DGCL and the complete text of our Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws. Our authorized capital stock consists of shares made up of 200,000,000 shares of common stock, par value $0.01 per share and 5,000,000 shares of |
|
| March 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37521 INDAPTUS THERAP |
|
| March 21, 2022 |
Exhibit 99.1 Indaptus Therapeutics Reports Fourth Quarter and Year End 2021 Financial Results and Provides Corporate Update NEW YORK (March 21, 2022) - Indaptus Therapeutics, Inc. (Nasdaq: INDP) (?Indaptus? or the ?Company?), today announces financial results for the fourth quarter and year ended December 31, 2021 and provides a corporate update. ?We enter 2022 excited about the future for Indaptu |
|
| March 21, 2022 |
EX-FILING FEES 4 ex107.htm Exhibit 107 EX-FILING FEES Calculation of Filing Fee Tables Form S-1 (Form Type) Indaptus Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offe |
|
| March 21, 2022 |
Exhibit 10.7 EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?), effective as of January 31, 2021 (the ?Effective Date?), is between Indaptus Therapeutics, Inc. (the ?Company?) and Boyan Litchev (the ?Executive?). WITNESSETH WHEREAS, the Company desires to employ the Executive as its Chief Medical Officer, and the Executive desires to accept such employment, on the terms and conditi |
|
| March 21, 2022 |
Power of Attorney for Mark J. Gilbert, M.D. Exhibit 24.2 POWER OF ATTORNEY March 21, 2022 The undersigned director of Indaptus Therapeutics, Inc. hereby constitutes and appoints Jeffrey A. Meckler and Nir Sassi, and each of them, with full power to act without the other, as such person?s true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, i |
|
| March 21, 2022 |
Exhibit 21.1 List of Subsidiaries of Indaptus Therapeutics, Inc.: Name Jurisdiction of Incorporation/Formation Intec Pharma Ltd. Israel Decoy Biosystems, Inc. Delaware |
|
| March 21, 2022 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 21, 2022 INDAPTUS THERAPEUTICS, INC. |
|
| March 21, 2022 |
As filed with the Securities and Exchange Commission on March 21, 2022 As filed with the Securities and Exchange Commission on March 21, 2022 Registration No. |
|
| March 21, 2022 |
Exhibit 10.6 EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?), effective as of January 1, 2022 (the ?Effective Date?), is between Intec Pharma Ltd. an Israeli company number 51-3022780 (the ?Company?), the wholly-owned subsidiary of Indaptus Therapeutics, Inc. (the ?Indaptus?) and Nir Sassi, ID [***] whose address is [***] (the ?Executive?). WITNESSETH WHEREAS, the Company desires |
|
| February 11, 2022 |
SC 13G/A 1 ea155267-13ga2intraindaptus.htm AMENDMENT NO. 2 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Indaptus Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 45339J105 (CUSIP Number) December 31, 2021 (Date of Event Which |
|
| February 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 1, 2022 INDAPTUS THERAPEUTICS, INC. |
|
| January 3, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 3, 2022 INDAPTUS THERAPEUTICS, INC. |
|
| January 3, 2022 |
Exhibit 99.1 Indaptus Therapeutics Announces Appointment of Boyan Litchev, M.D. as Chief Medical Officer Seasoned Drug Developer Brings More Than Twenty Years of Medical Leadership and Clinical Oncology Experience On Track to Initiate Phase 1 Study of Decoy20 in 2022 NEW YORK (January 3, 2022) - Indaptus Therapeutics, Inc. (Nasdaq: INDP) (?Indaptus? or the ?Company?), today announces the appointme |
|
| December 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 29, 2021 INDAPTUS THERAPEUTICS, INC. |
|
| November 30, 2021 |
As filed with the Securities and Exchange Commission on November 30, 2021 Registration No. |
|
| November 17, 2021 |
GAN / Gan Ltd / Anderson Glen R. Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Indaptus Therapeutics, Inc. (Name of Issuer) Ordinary Shares, Par Value $0.01 Per Share (Title of Class of Securities) 45339J 105 (CUSIP Number) Glen R. Anderson Anderson Family Trust 3274 Ross Road Palo Alto, CA 94303 +1.650.493.7500 (Name, Address and |
|
| November 15, 2021 |
Indaptus Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update Exhibit 99.1 Indaptus Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update NEW YORK (November 15, 2021) - Indaptus Therapeutics, Inc. (Nasdaq: INDP) (?Indaptus? or the ?Company?), today announces financial results for the third quarter ended September 30, 2021 and provides a corporate update. ?The third quarter was transformative for Indaptus as we successfully c |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40652 Indapt |
|
| November 15, 2021 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 15, 2021 INDAPTUS THERAPEUTICS, INC. |
|
| October 26, 2021 |
GAN / Gan Ltd / Lee Hoonmo Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Indaptus Therapeutics, Inc. (Name of Issuer) Ordinary Shares, Par Value $0.01 Per Share (Title of Class of Securities) 45339J 105 (CUSIP Number) Hoonmo Lee TY BIO INVESTMENT, INC. 2248 Seaview Dr. Fullerton, CA 92833 +1.213.610.7965 +82.10.6252.9873 (Nam |
|
| October 26, 2021 |
GAN / Gan Ltd / Newman Michael James Activist Investment SC 13D/A 1 formsc13da.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Indaptus Therapeutics, Inc. (Name of Issuer) Ordinary Shares, Par Value $0.01 Per Share (Title of Class of Securities) 45339J 105 (CUSIP Number) Michael J. Newman c/o Indaptus Therapeutics, Inc. 3 Columbus Circle, 15th Floor N |
|
| October 26, 2021 |
GAN / Gan Ltd / Anderson Glen R. Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Indaptus Therapeutics, Inc. (Name of Issuer) Ordinary Shares, Par Value $0.01 Per Share (Title of Class of Securities) 45339J 105 (CUSIP Number) Glen R. Anderson Anderson Family Trust 3274 Ross Road Palo Alto, CA 94303 +1.650.493.7500 (Name, Address and |
|
| September 30, 2021 |
Indaptus Therapeutics, Inc. 3 Columbus Circle, 15th Floor New York, NY 10019 Indaptus Therapeutics, Inc. 3 Columbus Circle, 15th Floor New York, NY 10019 September 30, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Indaptus Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-258854 Ladies and Gentlemen: On August 16, 2021, Indaptus Therapeutics, Inc. (the ?Company?) filed the Re |
|
| September 29, 2021 |
Indaptus Therapeutics, Inc. 5,590,910 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-259771 Indaptus Therapeutics, Inc. 5,590,910 Shares of Common Stock This prospectus relates to the resale, by the selling stockholders identified in this prospectus, of an aggregate of up to 5,590,910 shares of our common stock, par value $0.01, consisting of (i) 2,727,273 shares of common stock issuable upon the exercise of pre-funded warrants |
|
| September 28, 2021 |
Indaptus Therapeutics, Inc. 3 Columbus Circle, 15th Floor New York, NY 10019 Indaptus Therapeutics, Inc. 3 Columbus Circle, 15th Floor New York, NY 10019 September 28, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Indaptus Therapeutics, Inc. Registration Statement on Form S-1 File No. 333-259771 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Indaptus |
|
| September 24, 2021 |
EX-21.1 3 ex21-1.htm Exhibit 21.1 LIST OF SUBSIDIARIES Subsidiaries of Registrant Name Percentage Ownership State or Country of Organization Intec Pharma Ltd. 100% Israel Decoy Biosystems, Inc. 100% Delaware Intec Pharma Inc. 100%* Delaware * Wholly owned subsidiary of Intec Pharma Ltd. |
|
| September 24, 2021 |
As filed with the Securities and Exchange Commission on September 24, 2021 As filed with the Securities and Exchange Commission on September 24, 2021 Registration No. |
|
| August 27, 2021 |
As filed with the Securities and Exchange Commission on August 27, 2021 As filed with the Securities and Exchange Commission on August 27, 2021 Registration No. |
|
| August 19, 2021 |
GAN / Gan Ltd / Anderson Glen R. Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Indaptus Therapeutics, Inc. (Name of Issuer) Ordinary Shares, Par Value $0.01 Per Share (Title of Class of Securities) 45339J 105 (CUSIP Number) Glen R. Anderson Anderson Family Trust 3274 Ross Road Palo Alto, CA 94303 +1.650.493.7500 (Name, Address and T |
|
| August 18, 2021 |
As filed with the Securities and Exchange Commission on August 16, 2021 As filed with the Securities and Exchange Commission on August 16, 2021 Registration No. |
|
| August 16, 2021 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL information EX-99.2 4 ex99-2.htm Exhibit 99.2 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL information On August 3, 2021, (the “Closing Date”) Indaptus Therapeutics, Inc. (formerly Intec Parent, Inc.), a Delaware corporation (the “Company”), completed its merger with Decoy Biosystems, Inc., a Delaware corporation (“Decoy”) following the satisfaction or waiver of the conditions set forth in the Agreement a |
|
| August 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40652 Indaptus Th |
|
| August 16, 2021 |
Exhibit 99.1 DECOY BIOSYSTEMS, INC. UNAUDITED FINANCIAL STATEMENTS AS OF JUNE 30, 2021 AND DECEMBER 31, 2020 AND FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2021 AND 2020 DECOY BIOSYSTEMS, INC. TABLE OF CONTENTS Page Unaudited Financial Statements Unaudited Balance Sheets 3 Unaudited Statements of Operations 4 Unaudited Statements of Stockholders? Equity 5 Unaudited Statements of Cash Flows 6 Note |
|
| August 16, 2021 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 16, 2021 INDAPTUS THERAPEUTICS, INC. |
|
| August 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A (Amendment No. |
|
| August 16, 2021 |
As filed with the Securities and Exchange Commission on August 16, 2021 As filed with the Securities and Exchange Commission on August 16, 2021 Registration No. |
|
| August 16, 2021 |
Letter from Kesselman & Kesselman, dated August 16, 2021 Exhibit 16.1 August 16, 2021 Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Commissioners: We have read the statements made by Indaptus Therapeutics, Inc. (copy attached), which we understand will be filed with the Securities and Exchange Commission, pursuant to Item 4.01 of Form 8-K/A of Indaptus Therapeutics, Inc. dated August 12, 2021. We agree with the statements co |
|
| August 16, 2021 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION On August 3, 2021, (the ?Closing Date?) Indaptus Therapeutics, Inc. (formerly Intec Parent, Inc.), a Delaware corporation (the ?Company?), completed its merger with Decoy Biosystems, Inc., a Delaware corporation (?Decoy?) following the satisfaction or waiver of the conditions set forth in the Agreement and Plan of Merger (th |
|
| August 16, 2021 |
As filed with the Securities and Exchange Commission on August 16, 2021 As filed with the Securities and Exchange Commission on August 16, 2021 Registration No. |
|
| August 13, 2021 |
GAN / Gan Ltd / Lee Hoonmo Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Indaptus Therapeutics, Inc. (Name of Issuer) Ordinary Shares, Par Value $0.01 Per Share (Title of Class of Securities) 45339J 105 (CUSIP Number) Hoonmo Lee TY BIO INVESTMENT, INC. 2248 Seaview Dr. Fullerton, CA 92833 +1.213.610.7965 +82.10.6252.9873 (Name |
|
| August 13, 2021 |
GAN / Gan Ltd / Newman Michael James Activist Investment SC 13D 1 formsc13d.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Indaptus Therapeutics, Inc. (Name of Issuer) Ordinary Shares, Par Value $0.01 Per Share (Title of Class of Securities) 45339J 105 (CUSIP Number) Michael J. Newman c/o Indaptus Therapeutics, Inc. 3 Columbus Circle, 15th Floor New Yor |
|
| August 13, 2021 |
EX-99.2 2 ex99-2.htm Exhibit 99.2 Agreement of Joint Filing The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknow |
|
| August 6, 2021 |
EX-10.5 6 ex10-5.htm Exhibit 10.5 INDEMNIFICATION AGREEMENT THIS AGREEMENT (the “Agreement”) is made and entered into as of this day of between Indaptus Therapeutics, Inc., a Delaware corporation (“the Company”, which term shall include where appropriate any Enterprise (as hereafter defined) controlled directly or indirectly by the Company and any successor to the Company), and [] (“Indemnitee”). |
|
| August 6, 2021 |
Corporate Presentation dated August 3, 2021 Exhibit 99.2 |
|
| August 6, 2021 |
EX-10.7 7 ex10-7.htm Exhibit 10.7 FIRST AMENDMENT TO THE Indaptus Therapeutics, InC. 2021 STOCK INCENTIVE PLAN This Amendment to the Indaptus Therapeutics, Inc. 2021 Stock Incentive Plan (this “Amendment”) is made and entered into effective as of this 4th day of August, 2021 by Indaptus Therapeutics, Inc. RECITALS WHEREAS, stockholders approved the Intec Parent, Inc. 2021 Stock Incentive Plan on J |
|
| August 6, 2021 |
EX-10.3 4 ex10-3.htm Exhibit 10.3 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”), effective as of August 4, 2021 (the “Effective Date”), is between Indaptus Therapeutics, Inc. (the “Company”) and Walt A Linscott (the “Executive”). WITNESSETH WHEREAS, Intec Pharma Inc., a subsidiary of Intec Pharma Ltd., an Israeli corporation (“Intec”), entered into an employment agreement with |
|
| August 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 3, 2021 INDAPTUS THERAPEUTICS, INC. |
|
| August 6, 2021 |
Services Agreement between Nir Sassi and Indaptus Therapeutics, Inc., dated August 5, 2021 EX-10.4 5 ex10-4.htm Exhibit 10.4 SERVICES AGREEMENT This SERVICES AGREEMENT (this “Agreement”) is made and entered as of August 4, 2021, by and between Indaptus Therapeutics, Inc., a Delaware corporation (the “Company”) and Nir Sassi of Rothschild 69b Kadima, Israel (the “Service Provider”) (The Company and the Service Provider shall additionally be referred as each, a “Party” and collectively, t |
|
| August 6, 2021 |
EX-99.3 5 ex99-3.htm Exhibit 99.3 DECOY BIOSYSTEMS, INC. UNAUDITED FINANCIAL STATEMENTS AS OF MARCH 31, 2021 AND DECEMBER 31, 2020 AND FOR THE THREE MONTHS ENDED MARCH 31, 2021 AND 2020 DECOY BIOSYSTEMS, INC. TABLE OF CONTENTS Page Unaudited Financial Statements Unaudited Balance Sheets 3 Unaudited Statements of Operations 4 Unaudited Statements of Stockholders’ Equity 5 Unaudited Statements of Ca |
|
| August 6, 2021 |
Intec Closes Merger with Decoy Biosystems EX-99.1 8 ex99-1.htm Exhibit 99.1 Intec Closes Merger with Decoy Biosystems Completes $30 Million Private Placement Changes Corporate Name to Indaptus Therapeutics to Reflect Clinical Focus NEW YORK, Aug. 3, 2021 /PRNewswire/ —Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company,” and formerly, Intec Parent, Inc.) today announced the closing of its previously announced merger wit |
|
| August 6, 2021 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF INTEC PARENT, INC. Pursuant to Section 242 of the Delaware General Corporation Law (the ?DGCL?), Intec Parent, Inc., a Delaware corporation (the ?Company?), by its undersigned representative hereunto duly authorized, hereby adopts the following Certificate of Amendment (this ?Amendment?) to its Amended |
|
| August 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 3, 2021 INDAPTUS THERAPEUTICS, INC. |
|
| August 6, 2021 |
Exhibit 10.2 EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?), effective as of August 4, 2021 (the ?Effective Date?), is between Indaptus Therapeutics, Inc. (the ?Company?) and Michael J. Newman (the ?Executive?). WITNESSETH WHEREAS, the Company desires to employ the Executive as its Chief Science Officer, and the Executive desires to accept such employment, on the terms and condi |
|
| August 6, 2021 |
Intec Closes Merger with Decoy Biosystems Exhibit 99.1 Intec Closes Merger with Decoy Biosystems Completes $30 Million Private Placement Changes Corporate Name to Indaptus Therapeutics to Reflect Clinical Focus NEW YORK, Aug. 3, 2021 /PRNewswire/ ?Indaptus Therapeutics, Inc. (Nasdaq: INDP) (?Indaptus? or the ?Company,? and formerly, Intec Parent, Inc.) today announced the closing of its previously announced merger with Decoy Biosystems, I |
|
| August 6, 2021 |
EX-10.1 2 ex10-1.htm Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”), effective as of August 4, 2021 (the “Effective Date”), is between Indaptus Therapeutics, Inc. (the “Company”) and Jeffrey A. Meckler (the “Executive”). WITNESSETH WHEREAS, Intec Pharma Inc., a subsidiary of Intec Pharma Ltd., an Israeli corporation (“Intec”), entered into an employment agreement wi |
|
| July 29, 2021 |
Exhibit 10.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| July 29, 2021 |
Form of Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July 23, 2021, between Intec Parent, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set f |
|
| July 29, 2021 |
Exhibit 10.5 Execution Version July 12, 2021 STRICTLY CONFIDENTIAL Intec Pharma Ltd. 12 Hartom Street Har Hotzvim, Jerusalem 9777512 Israel Attn: Jeffrey A. Meckler, Chief Executive Officer and Vice Chairman Dear Mr. Meckler: This letter agreement (this “Agreement”) constitutes the agreement between Intec Pharma Ltd. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”), that Wainwright sh |
|
| July 29, 2021 |
EX-10.1 2 ex10-1.htm Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July 23, 2021, between Intec Parent, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms |
|
| July 29, 2021 |
Exhibit 10.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| July 29, 2021 |
EX-10.2 3 ex10-2.htm Exhibit 10.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT T |
|
| July 29, 2021 |
Exhibit 10.4 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made and entered into as of July 23, 2021, by and between Intec Parent, Inc., a Delaware corporation (the ?Company?), and each of the several purchasers signatory hereto (each such purchaser, a ?Purchaser? and, collectively, the ?Purchasers?). This Agreement is made pursuant to the Securities Purcha |
|
| July 29, 2021 |
EX-10.5 6 ex10-5.htm Exhibit 10.5 Execution Version July 12, 2021 STRICTLY CONFIDENTIAL Intec Pharma Ltd. 12 Hartom Street Har Hotzvim, Jerusalem 9777512 Israel Attn: Jeffrey A. Meckler, Chief Executive Officer and Vice Chairman Dear Mr. Meckler: This letter agreement (this “Agreement”) constitutes the agreement between Intec Pharma Ltd. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright” |
|
| July 29, 2021 |
425 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 23, 2021 INTEC PARENT, INC. (Exact name of registrant as specified in its charter) Delaware 333-255389 86-3158720 (State or other jurisdiction of incorporation) (C |
|
| July 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 23, 2021 INTEC PARENT, INC. |
|
| July 29, 2021 |
Exhibit 10.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| July 29, 2021 |
Form of Registration Rights Agreement Exhibit 10.4 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of July 23, 2021, by and between Intec Parent, Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Securities Purcha |
|
| July 23, 2021 |
Amended and Restated Bylaws of Intec Parent, Inc., dated as of July 23, 2021 Exhibit 3.2 These bylaws of Intec Parent, Inc. (the “Corporation”) were adopted as of July 23, 2021 (these “Bylaws”). ARTICLE 1 CORPORATE OFFICES 1.1 REGISTERED OFFICE. The registered office of the Corporation shall be fixed in the Corporation’s Certificate of Incorporation, as the same may be amended or restated from time to time (the “Certificate of Incorporation”). 1.2 OTHER OFFICES. The Corpor |
|
| July 23, 2021 |
EX-3.1 2 ex3-1.htm Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF INTEC PARENT, INC. Intec Parent, Inc., a corporation hereby organized and existing under the laws of the State of Delaware (the “Corporation”), does hereby certify: A. The Corporation was originally incorporated under the name of Intec Parent, Inc., and the original certificate of incorporation of the Corporation w |
